Evolve HealthCare Partners, (“Evolve”), the European mid-market specialist investor in healthcare, together with the existing institutional shareholders, have led a capital injection in Cera Care (“Cera” or the “Company”) to support and accelerate its continuous growth.
Evolve has co-invested alongside Schroder Adveq.
The global Covid-19 crisis will lead to unprecedented change.
Certain healthcare sectors will be re-defined as strategic infrastructure and new trends will emerge that will persist beyond the crisis.
We examine the five key post-Covid-19 trends and the likely investment opportunities that will arise.
Evolve Healthcare Partners featured in the Laing & Buisson Private Equity in Healthcare Market Report 4ed
In addition to traditional levers, a more pragmatic and hands on approach is required to unlock the full potential of healthcare private equity investments